- The first patient has been treated in a confirmatory study called EVAS2 assessing Endologix's (NASDAQ:ELGX +0.1%) next-generation Nellix EndoVascular Aneurysm Sealing (EVAS) System. The company expects U.S. approval by late 2020.
- Previously: Endologix on go to launch study of Nellix EVAS for infrarenal abdominal aortic aneurysms; shares ahead 5% premarket (Oct. 6, 2017)